Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 6/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | VNN1 | O95497 | 3/20 | 0.32 |
| ▸ | BTD | P43251 | 2/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416429 | 1.00 | JAK1 (0.33) | JAK1JAK2JAK3TYK2VNN1 | |
| SCHEMBL5127466 | 1.00 | JAK1 (0.33) | JAK1JAK2JAK3TYK2VNN1 | |
| SCHEMBL932224 | 0.91 | KDM4E (0.35) | JAK2F2RKDM4EALDH1A1 | |
| SCHEMBL28168621 | 0.88 | VNN1 (0.40) | VNN1BTDALDH1A1 | |
| SCHEMBL27510701 | 0.85 | F2R (0.36) | JAK1JAK2JAK3TYK2VNN1 | |
| SCHEMBL30441232 | 0.84 | VNN1 (0.35) | VNN1BTD | |
| SCHEMBL27948 | 0.82 | — | — | |
| SCHEMBL16887553 | 0.82 | DPP4 (0.38) | JAK1JAK2JAK3KDM4E | |
| SCHEMBL15796013 | 0.82 | JAK1 (0.32) | JAK1JAK2JAK3TYK2VNN1 | |
| SCHEMBL27626212 | 0.82 | GAA (0.33) | JAK1JAK2JAK3TYK2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | claimed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | claimed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | claimed |
| US-20240279338-A1 | Combination Treatment of Cancer | ARES TRADING SA (CH) | 2024-08-22 | — | — | US | disclosed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-1802307-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| EP-1802307-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-07-04 | — | — | EP | disclosed |
| CN-1882576-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006040192-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | HRH4, HRH3, HRH2 | JAK1 1443/4885JAK2 812/4885JAK3 1813/4885 |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | JAK1 293/4885JAK2 385/4885JAK3 668/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | JAK1 696/4885JAK2 926/4885JAK3 1213/4885 |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, AMPD2 | JAK1 410/4885JAK2 342/4885JAK3 1099/4885 |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | JAK1 293/4885JAK2 385/4885JAK3 668/4885 |
| US-20240279338-A1 | Combination Treatment of Cancer | CD274, PDCD1, ENTPD1 | JAK1 907/4885JAK2 982/4885JAK3 1518/4885 |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, AMPD2 | JAK1 410/4885JAK2 342/4885JAK3 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.